JP4695837B2 - 複合エストロゲン天然混合物を調節して放出するマトリックス−被膜錠剤 - Google Patents

複合エストロゲン天然混合物を調節して放出するマトリックス−被膜錠剤 Download PDF

Info

Publication number
JP4695837B2
JP4695837B2 JP2003552269A JP2003552269A JP4695837B2 JP 4695837 B2 JP4695837 B2 JP 4695837B2 JP 2003552269 A JP2003552269 A JP 2003552269A JP 2003552269 A JP2003552269 A JP 2003552269A JP 4695837 B2 JP4695837 B2 JP 4695837B2
Authority
JP
Japan
Prior art keywords
matrix
pharmaceutical
weight
coated tablet
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003552269A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005513059A5 (enExample
JP2005513059A (ja
Inventor
トゥムベック ベルント
ブッデ クラウス
クリステン ゲルハルト
ヴィアルツ マルギット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Original Assignee
Solvay Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals GmbH filed Critical Solvay Pharmaceuticals GmbH
Publication of JP2005513059A publication Critical patent/JP2005513059A/ja
Publication of JP2005513059A5 publication Critical patent/JP2005513059A5/ja
Application granted granted Critical
Publication of JP4695837B2 publication Critical patent/JP4695837B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2003552269A 2001-12-14 2002-12-12 複合エストロゲン天然混合物を調節して放出するマトリックス−被膜錠剤 Expired - Fee Related JP4695837B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01129830 2001-12-14
EP01129830.4 2001-12-14
PCT/EP2002/014103 WO2003051336A1 (de) 2001-12-14 2002-12-12 Matrix-filmtablette mit kontrollierter freisetzung von natürlichen gemischen konjugierter oestrogene

Publications (3)

Publication Number Publication Date
JP2005513059A JP2005513059A (ja) 2005-05-12
JP2005513059A5 JP2005513059A5 (enExample) 2006-01-19
JP4695837B2 true JP4695837B2 (ja) 2011-06-08

Family

ID=8179548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003552269A Expired - Fee Related JP4695837B2 (ja) 2001-12-14 2002-12-12 複合エストロゲン天然混合物を調節して放出するマトリックス−被膜錠剤

Country Status (18)

Country Link
US (1) US8268351B2 (enExample)
EP (1) EP1465602B1 (enExample)
JP (1) JP4695837B2 (enExample)
CN (1) CN100542538C (enExample)
AR (1) AR037760A1 (enExample)
AT (1) ATE438384T1 (enExample)
AU (1) AU2002361396B2 (enExample)
BR (1) BR0215044A (enExample)
CA (1) CA2470207C (enExample)
DE (1) DE50213751D1 (enExample)
DK (1) DK1465602T3 (enExample)
ES (1) ES2328910T3 (enExample)
MX (1) MXPA04005769A (enExample)
PL (1) PL205739B1 (enExample)
PT (1) PT1465602E (enExample)
SI (1) SI1465602T1 (enExample)
TW (1) TWI252111B (enExample)
WO (1) WO2003051336A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7303763B2 (en) * 2001-02-12 2007-12-04 Watson Laboratories, Inc. Compositions for conjugated estrogens and associated methods
ES2377729T3 (es) * 2002-02-21 2012-03-30 Valeant International (Barbados) Srl Formulaciones de liberación modificada de al menos una forma de tramadol
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US6992075B2 (en) * 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
GB0329498D0 (en) * 2003-12-19 2004-01-28 Novartis Ag Organic compounds
JP4521554B2 (ja) * 2004-03-31 2010-08-11 マイラン製薬株式会社 シクロスポリン製剤
DE102004035938A1 (de) * 2004-07-23 2006-02-16 Röhm GmbH & Co. KG Verfahren zur Herstellung von überzogenen Arzneiformen mit stabilem Wirkstofffreigabeprofil
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
JP5162141B2 (ja) * 2007-02-20 2013-03-13 エスエス製薬株式会社 フィルムコーティング用組成物
JP4864024B2 (ja) * 2008-02-15 2012-01-25 エスエス製薬株式会社 時限放出製剤
US20090232897A1 (en) * 2008-03-14 2009-09-17 Bijayananda Sahoo Pharmaceutical compositions comprising conjugated estrogens

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3753767A (en) * 1971-08-02 1973-08-21 Colgate Palmolive Co Method of sugar-coating tablets
DE3535536A1 (de) * 1985-10-04 1987-04-09 Lentia Gmbh Verfahren zum gleichzeitigen trocknen und granulieren von extraktstoffen aus enteiweisstem kaelberblut
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
EP0322020A1 (en) * 1987-12-22 1989-06-28 Akzo N.V. Pharmaceutical dosage unit for treating climacteric complaints and osteoporosis
HU9500322D0 (en) * 1994-02-08 1995-03-28 Solvay Deutschland Process for separating estrogenes from the urine of mares with foal
US5458887A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
DE4429398C2 (de) * 1994-08-09 1997-09-11 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Kontrazeption
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
CN1101683C (zh) * 1996-08-30 2003-02-19 索尔瓦药物有限公司 由牝马尿获取雌激素的方法
CN1101682C (zh) * 1996-08-30 2003-02-19 索尔瓦药物有限公司 由牝马尿液获取雌激素的方法
DK0923381T3 (da) 1996-08-30 2004-05-10 Solvay Pharm Gmbh Fremgangsmåde til fremstilling af östrogener ud fra hoppeurin
ATE264110T1 (de) 1996-08-30 2004-04-15 Solvay Pharm Gmbh Prozess zur gewinnung von oestrogenen aus stutenharn
AU8699298A (en) * 1997-08-11 1999-03-01 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
US6022554A (en) * 1997-12-15 2000-02-08 American Home Products Corporation Polymeric microporous film coated subcutaneous implant
DE19845358A1 (de) * 1998-10-02 2000-04-06 Roehm Gmbh Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe
EP1027888B1 (en) * 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
DK1183014T3 (da) * 1999-06-14 2004-02-09 Cosmo Spa Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
US20010034340A1 (en) * 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy

Also Published As

Publication number Publication date
ATE438384T1 (de) 2009-08-15
EP1465602B1 (de) 2009-08-05
CN100542538C (zh) 2009-09-23
CA2470207C (en) 2012-07-10
AU2002361396B2 (en) 2008-02-14
AR037760A1 (es) 2004-12-01
US20050019408A1 (en) 2005-01-27
WO2003051336A1 (de) 2003-06-26
JP2005513059A (ja) 2005-05-12
CN1607943A (zh) 2005-04-20
PL205739B1 (pl) 2010-05-31
EP1465602A1 (de) 2004-10-13
AU2002361396A1 (en) 2003-06-30
DK1465602T3 (da) 2009-09-28
MXPA04005769A (es) 2004-09-10
HK1075005A1 (zh) 2005-12-02
TW200408414A (en) 2004-06-01
TWI252111B (en) 2006-04-01
ES2328910T3 (es) 2009-11-19
BR0215044A (pt) 2004-11-03
US8268351B2 (en) 2012-09-18
CA2470207A1 (en) 2003-06-26
DE50213751D1 (de) 2009-09-17
PL369367A1 (en) 2005-04-18
SI1465602T1 (sl) 2009-12-31
PT1465602E (pt) 2009-09-07

Similar Documents

Publication Publication Date Title
JP4695838B2 (ja) 結合型エストロゲン天然混合物を錠剤化するためのプレ調製物
JP4749639B2 (ja) 味がマスクされ、活性成分を即時放出する、被覆された顆粒の製造方法
JP4017664B2 (ja) 複合エストロゲンの医薬組成物およびその使用方法
US5275824A (en) Therapeutic compositions with controlled release of medicaments supported on crosslinked polymers and coated with polymer films, and their preparation process
JP2001517616A (ja) 活性成分としてクロドロン酸塩および賦形剤としてケイ化微晶質セルロースを含む医薬製剤
JP4695837B2 (ja) 複合エストロゲン天然混合物を調節して放出するマトリックス−被膜錠剤
JP2003513882A (ja) ジバルプロエックスナトリウムの制御放出製剤
EP2063876A1 (en) Extended release pharmaceutical formulation of metoprolol and process for its preparation
WO2022012172A1 (zh) 一种难溶性药物口服缓释组合物及其制备方法
JPH0753663B2 (ja) チアミン塩の顆粒，その製造法および錠剤
ZA200200380B (en) Low-dose tablets and preparation process.
JP2009519313A (ja) 医薬組成物
HK1075005B (en) Matrix film tablets for the controlled release of natural mixtures of conjugated estrogen
JPH11510158A (ja) 自由流動性圧縮可能粉末を製造する同時加工方法及びこれから錠剤を製造する方法
JPH02282323A (ja) 徐放性錠剤の製造方法
HK1104220B (en) Pre-formulation for the tabletting of natural mixtures of conjugated estrogens
JP2018070541A (ja) ソリフェナシン含有医薬組成物とその製造方法
CN115702896A (zh) 一种异喹啉药物制剂
CZ20031202A3 (cs) Farmaceutická kompozice obsahující jako účinnou látku ribavirin a způsob její výroby

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090520

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090729

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100219

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101008

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101020

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110210

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110228

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140304

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140304

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees